Leviticus Cardio News
15 articles
Israeli-Welsh collaboration reports success with implantable heart pumps
Breakthrough in Device Therapy for Patients with Late-Stage Heart Disease
Calon Cardio-Technology Ltd and Leviticus Cardio Ltd have successfully completed a 60-day in-vivo pre-clinical study of a fully implantable Ventricular Assist Device (FiVAD). The device combines Calon Cardios MiniVAD with Leviticus Cardios wireless energy recharging system, allowing patients a full day without a cable or connection to any external equipment. The successful elimination of the electric power cable is a major step forward in improving the quality of life for severely ill patients. The trial was conducted at the Catholic University of Leuven, in Belgium.
PartnersInvestment
Leviticus Cardio charges towards the market
A collaboration between Jarvik Heart and Leviticus Cardio has come closest to achieving the goal of a wholly implanted left ventricular assist device (LVAD) for patients with severe heart failure. The Fivad device, a version of the Jarvik 2000 LVAD, was implanted in a human for the first time this year and data on two patients have been presented at a conference. The device, which is powered wirelessly through the skin using Leviticus Cardios coplanar energy transfer technology, could be a disruptive advance in the field. The next step is to start a clinical trial, with European CE mark expected in around 18 months and US approval in three years. Leviticus Cardio is raising $20m in funding to bring its technology to market.
PartnersInvestment
Man Receives World's First Wirelessly Powered Heart Pump
Leviticus Cardio, an Israeli company, has partnered with Jarvik Heart to successfully implant a completely implanted ventricular assist device (VAD) powered by Leviticus Cardios Coplanar Energy Transfer (CET) system. The system eliminates the need for a power cable protruding through the skin, reducing the risk of infection and improving patient comfort and independence. The CET system consists of a coil ring implanted around the lungs, an internal battery and controller, and external power components. The system can be used with all currently available VAD devices and provides up to 30 Watts of continuous power. Patients can be free from external power components for up to six hours or more. This development has the potential to significantly improve the use of heart pumps for long periods of time.
Customers
Wireless Heart Pump Technology Implanted in a Patient for the First Time
Israel-based Leviticus Cardio has developed a wireless charging technology for left ventricular assist devices (VADs). The technology uses an external electromagnetic transmitter to charge an implanted battery, eliminating the need for a permanent exit wound. The company recently performed the first surgery on a human using the wirelessly charged pump. Leviticus Cardio received a $950,000 grant from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation and plans to use the funding to update the product, start clinical trials, and bring the product to market in the U.S. and Europe within two to three years.
CustomersInvestment
Leviticus Cardio and Jarvik Heart Awarded R&D Grant From the Prestigious BIRD Foundation
Leviticus Cardio and Jarvik Heart have been awarded a $950,000 grant from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation. The grant will help fund the ongoing development of a fully implanted wireless VAD system which utilizes Jarvik Hearts pump together with Leviticus CET technology. The funding will be integrated into the first phase of the project, designed to reach clinical regulatory trials for the hybrid system. Leviticus Cardios CEO expressed gratitude for the grant and mentioned the achievement of significant milestones. Jarvik Hearts president and COO stated that the goal of both companies is to change the lives of heart failure patients with the wireless system.
Investment
Leviticus Cardio Announces Success of Groundbreaking Six Month Chronic Animal Study
Leviticus Cardio has successfully completed a 180-day preclinical chronic animal study to evaluate its CET technology in combination with a commercial heart pump. The ongoing trial is being conducted at a renowned animal facility operated by the Catholic University of Leuven, Belgium. Leviticus has also raised additional funds to proceed with the first in human trial. The success of the trial and the additional resources received are seen as a milestone for the CET system. Leviticus Cardio aims to improve the clinical outcome for patients with an implanted LVAD. Jarvik Heart Inc. is the partner company that manufactures the LVAD used in combination with Leviticus CET technology.
PartnersInvestment
Leviticus Cardio successfully completes its third chronic animal study
Leviticus Cardio, an Israel company, announces the successful completion of a preclinical chronic animal study to evaluate its CET technology in combination with a commercial heart pump. This achievement paves the way for first in human trials expected in a matter of months.
PartnersCustomers
Leviticus Cardio Announces Successful Animal Trial Demonstrating Wireless Power to Jarvik 2000
Leviticus Cardio announces the successful animal implantation of the worlds first Hybrid Wireless Fully Implanted Ventricular Assisted System (Hybrid FILVAS). The new cardio device, designed for human patients with chronic heart conditions, can be powered wirelessly or with back-up power through a conventional driveline. Leviticus Cardios wireless Coplanar Energy Transfer (CET) system powers Ventricular Assist Devices (VADs) used to support patients with heart failure. The company is backed by the Israeli Innovation Authority (IIA) and venture capital investors. The animal trial was conducted with the Jarvik 2000. The article highlights the partnership between Leviticus Cardio and Jarvik Heart, an early LVAD innovator.
Partners
Leviticus Cardio successfully completes long-term animal study - The Trendlines Group
Leviticus Cardio Achieves Successful Transcutaneous Coplanar Energy Transfer in Chronic Animal Model
Leviticus Cardio announces positive results from a preclinical study evaluating their transcutaneous Coplanar Energy Transfer (CET) system. The study showed that the device was well tolerated in animals for 28 days and demonstrated stable and consistent energy transfer. The company believes that the CET system has the potential to improve the quality of life for patients with ventricular assist devices. Leviticus Cardio has also achieved ISO13485 certification, a critical step towards manufacturing their product. Major investors in the company include The Trendlines Group, a consortium of cardiovascular physicians, private investors, and Israels Office of the Chief Scientist.
Investment
Leviticus Cardio Completes Finance Round
Leviticus Cardio, a medical device company, has successfully raised over $1.5 million in its latest round of financing. The funds will allow the company to commence its first-in-man feasibility study with its wireless energy transfer technology for LVAD patients. The study will be presented at ISHLT 2015 in April 2015. Leviticus Cardio is in discussions with key LVAD centers in Europe to determine participation in the study. The company aims to improve the quality of life for destination therapy patients and patients awaiting a heart transplant. The wireless system, named Coplanar Energy Transfer (CET), aims to eliminate complications related to the driveline. Leviticus Cardio has raised a total of $3 million in private venture capital and government funding. Major investors include The Trendlines Group, cardiovascular physicians, private investors, and Israels Office of the Chief Scientist.
Investment
Wireless heart failure device co Leviticus Cardio raises NIS 4m
Leviticus Cardio, a portfolio company of Trendlines International Ltd., has completed a financing round of NIS 4 million. The round was led by a group of American investors who specialize in the LVAD field. Leviticus Cardio is developing a wireless device for patients with heart failure. The wireless transfer of energy using CET technology is seen as a game changer in the LVAD market, improving the quality of life for patients undergoing transplants.
Investment
Wireless heart failure device co Leviticus Cardio raises NIS 4m - Globes
Leviticus Cardio has successfully completed a financing round, raising NIS 4 million. The round was led by a group of American investors, some of whom specialize in the left ventricular assistance device (LVAD) field, making them a strategic asset for the company. Leviticus Cardio, a Trendlines International Ltd. portfolio company, is developing a wireless device to operate LVADs for heart failure patients. The companys founder and CEO, Michael Zilbershlag, highlighted the significance of their wireless energy transfer technology, which enhances the quality of life for patients undergoing transplants. This development marks a positive growth trajectory for the company.
Investment
Leviticus Cardio Completes Successful Wireless Energy System for VADs Animal Trial
Leviticus Cardio performed a successful animal surgical trial using its wireless coplanar energy transfer system (CET) for ventricular assist devices (VAD). The trial achieved a 75 percent full system efficiency rate. Leviticus Cardios CET system powers the VAD without wires, reducing complications and improving mobility for patients.
Partners
